Durable radiologic and clinical disease stability beyond PSA progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA)

被引：0
|
作者：
Bianchini, Diletta
Sandhu, Shahneen Kaur
Cassidy, Amy Mulick
Zivi, Andrea
Mezynski, Janusz
Mukherji, Deborah
Pezaro, Carmel Jo
Reid, Alison Helen
Oommen, Nikhil Babu
Olmos, David
Omlin, Aurelius Gabriel
Sarvadikar, Ajit
Thompson, Emilda
Hunt, Joanne
Sheridan, Elizabeth
Attard, Gerhardt
De Bono, Johann Sebastian
机构：
[1] Royal Marsden Hosp, Sutton, Surrey, England
[2] Inst Canc Res, Sutton, Surrey, England
[3] Royal Marsden Fdn Trust, Sutton, Surrey, England
[4] Royal Marsden Hosp, Dublin, Ireland
[5] Royal Marsden NHS Fdn Trust, London, England
[6] Inst Canc Res, London SW3 6JB, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4553
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Assessment of serial serum chromogranin A (CGA) and CGA/PSA ratio and treatment response with abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC).
    Lewis, Akeem Ronell
    Costello, Brian Addis
    Quevedo, Fernando
    Pagliaro, Lance C.
    Weinshilboum, Richard M.
    Wang, Leiwei
    Kalari, Krishna Rani
    Kohli, Manish
    Tan, Winston
    Giridhar, Karthik
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17036 - E17036
  • [22] Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
    Becker, Daniel J.
    Iyengar, Arjun D.
    Punekar, Salman R.
    Ng, Jason
    Zaman, Anika
    Loeb, Stacy
    Becker, Kevin D.
    Makarov, Danil
    ANTICANCER RESEARCH, 2019, 39 (05) : 2467 - 2473
  • [23] Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer
    Stover, J. T.
    Moore, R. A.
    Davis, K.
    Harrison, M. R.
    Armstrong, A. J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2015, 18 (02) : 161 - 166
  • [24] Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Nanus, David M.
    Posadas, Edwin M.
    Petrylak, Daniel Peter
    Bruce, Justine Yang
    Lim, Emerson A.
    Peng, Weimin
    Maul, Raymond Scott
    Gonzalez, Martha
    Tran, Namphuong
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [25] Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Schnadig, Ian D.
    Bhor, Menaka
    Vogelzang, Nicholas J.
    Hennessy, Daniel
    Nicacio, Leonardo V.
    Berry, William R.
    Hutson, Thomas E.
    Fleming, Mark T.
    Cowey, C. Lance
    Saravanan, Shanmugapriya
    Dhanda, Rahul
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [26] PSA progression compared to radiographic or clinical progression in metastatic castration-resistant prostate cancer patients treated with enzalutamide
    Gandhy, Shruti U.
    Karzai, Fatima
    Marte, Jennifer L.
    Bilusic, Marijo
    McMahon, Sheri
    Strauss, Julius
    Couvillon, Anna
    Williams, Monique
    Hankin, Amy
    Steinberg, Seth M.
    Figg, William Douglas
    Arlen, Philip M.
    Dahut, William L.
    Gulley, James L.
    Madan, Ravi Amrit
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [27] The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
    Cem, Onal
    Sedef, Ali Murat
    Kose, Fatih
    Oymak, Ezgi
    Guler, Ozan Cem
    Sumbul, Ahmet Taner
    Aksoy, Sercan
    Yildrim, Berna Akkus
    Besen, Ali Ayberk
    Mullaoglu, Sadik
    Mertsoylu, Huseyin
    Ozyigit, Gokhan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [28] Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC)
    Bianchini, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Rathkopf, Dana
    Smith, Matthew R.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Lee, Ji Youl
    Small, Eric J.
    Gomes, Andrea J. Pereira De Santana
    Roubaud, Guilhem
    Saad, Marniza
    Zurawski, Bogdan
    Sakalo, Valerii
    Mason, Gary E.
    Francis, Peter
    Ms, George Wang
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
  • [30] Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC)
    Efstathiou, Eleni
    Titus, Mark Anton
    Wen, Sijin
    SanMiguel, Aileen
    Hoang, Anh
    De Haas-Amatsaleh, Angela
    Perabo, Frank
    De Phung
    Troncoso, Patricia
    Ouatas, Taoufik
    Logothetis, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345